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Introduction
Frontotemporal lobar degeneration (FTLD) represents a heterogeneous group of neurodegenerative disorders characterized by neuronal loss in the frontal and temporal lobes of the brain. Clinically, two entities are defined: the behavioral variant of frontotemporal dementia (bvFTD) with main changes in personality and behavior (Neary et al., 1998; Rascovsky et al., 2011) and primary progressive aphasia (PPA) with language disturbances (Gorno-Tempini et al., 2011; Neary et al., 1998) . PPA is further subdivided into progressive non-fluent aphasia (PNFA), characterized by apraxia of speech and/or agrammatism, semantic dementia (SD), characterized by impaired confrontation naming and single word comprehension, and logopenic variant PPA, characterized by impaired word retrieval and a deficit in repetition of sentences and, in contrast with the other two PPA variants, mostly associated with underlying atypical AD pathology (Gorno-Tempini et al., 2011; Neary et al., 1998) . At neuropathology, FTLD brains show protein inclusions in degenerating neurons, and based on the particular inclusion protein, FTLD can be further subdivided into FTLD-TDP (TAR DNA-binding protein 43kDa), FTLD-tau (tau), FTLD-FUS (fused in sarcoma), FTLD-UPS (ubiquitin proteasome system) or FTLD-ni (no inclusions) .
About 30 to 50% of frontotemporal dementia (FTD) patients have a positive family history, indicating a strong genetic contribution. In 10 to 23% of FTD families the segregation is compatible with autosomal dominant inheritance (Goldman et al., 2007) . So far, seven causal FTD genes have been identified: microtubule-associated protein tau (MAPT) (Hutton et al., 1998) , valosin-containing protein (VCP) (Watts et al., 2004) , charged multivesicular body protein 2B (CHMP2B) (Skibinski et al., 2005) , progranulin (GRN) (Baker et al., 2006; Cruts et al., 2006) , chromosome 9 open reading frame 72 (C9orf72) (DeJesus-Hernandez et al., 2011; Gijselinck et al., 2012; Renton et al., 2011) , sequestosome 1 (SQSTM1) (Rubino et al., 2012; van der Zee et al., 2014) and TANK-binding kinase 1 (TBK1) (Gijselinck et al., 2015; Pottier et al., 2015) .
GRN is the second major mutated gene after C9orf72, with loss-of-function mutations (Cruts et al., 2006; Cruts et al., 2012; Sleegers et al., 2009) leading to a reduction of GRN levels in CSF and serum or plasma, supporting haploinsufficiency as the underlying disease mechanism (Finch
genome-wide association (GWA) study of plasma GRN levels in FTD patients and controls, identified a significant association with two single nucleotide polymorphisms (SNPs), rs646776
and rs611917, located 34 kb and 37 kb downstream of SORT1 (Carrasquillo et al., 2010) . In the present study, we investigated a role SORT1 in the genetic etiology of FTD.
Methods
Patient/control study populations
The Belgian patients and control individuals were ascertained through the Belgian Neurology (BELNEU) Consortium and consisted of 636 index FTD patients (mean onset age 63 ± 10 years)
with a clinical diagnosis of probable or possible FTD (n=593), possible corticobasal syndrome (CBS, n=15), possible progressive supranuclear palsy syndrome (PSPS, n=27) or a differential diagnosis of PSPS or CBS (n=1). All patients were evaluated by detailed clinical history of patients and family, neurological examination and neuroimaging. Clinical diagnosis was reached according to established clinical criteria (Alexander et al., 2014; Gorno-Tempini et al., 2011; Litvan et al., 1996; Rascovsky et al., 2011) . For 408 FTD patients, information was available on the clinical subtype: 286 received a diagnosis of possible or probable bvFTD (45.0% of the entire cohort) and 123 of PPA (19.3%). From the latter, 50 were diagnosed with SD (7.9%), 42 with PNFA (6.6%) and 4 with logopenic PPA (0.6%). All patients with a clinical diagnosis of FTD combined with motor neuron disease were excluded from this study. For 5.7% of the patients (n=36), neuropathological examination was available. FTLD-TDP was the most frequent pathology (n=18; 2.8%), followed by FTLD-tau (n=11; 1.7%; includes three PSP and one CBD patients), and FTLD-UPS (n=2; 0.3%); few received a pathological diagnosis consistent with FTLD-U not further specified (n=4; 0.6%), and one was reported negative for TDP-43 and tau positive inclusions (n=1; 0.2%). A family history of dementia, defined by at least one first-degree relative with dementia, was present in 30.3% (n=193) of patients. We also included 1,066 unrelated age-and geographically matched control individuals (mean age at inclusion 67 years ± 13 years), who were negative for a personal or family history of a neurodegenerative disease and had a mini-mental state examination (MMSE) or Montreal Cognitive Assessment (MoCA) score above 25 (Folstein et al., 1975; Nasreddine et al., 2005) .
Patients and control persons were genetically profiled for common genes associated with the FTD-ALS spectrum (GRN, MAPT, TBK1, VCP, TARDBP and FUS) or AD (APP, PSEN1, PSEN2). Custom gene panels were designed using amplicon target amplification technology (Agilent, https://www.agilent.com) for re-sequencing on a MiSeq (Illumina) platform. The
C9orf72 repeat was typed by repeat-primed PCR and fragment-length analysis, as described (Gijselinck et al., 2012) .
Three independently sampled patient/control cohorts were obtained via the European EarlyOnset Dementia (EU EOD) Consortium, described in detail in previous studies (van der Zee et al., 2013; van der Zee et al., 2017) . The European cohorts together consisted of 1,155 FTD patients originating from Spain (n = 438), Italy (n = 486) and Portugal (n = 231), and 1,161
geographically-matched controls from Spain (n = 502), Italy (n = 537) and Portugal (n = 122).
Characteristics of the patient and control cohorts are listed in Table S1 and have been published in more detail (van der Zee et al., 2017).
Ethical assurances
For all participants, informed consent for participation in clinical and genetic studies was obtained according to sampling and study protocols that were approved by the local Ethics
Committees of the collaborating medical centers. The protocols for the clinical and genetic studies were approved by the Ethics Committee of the University of Antwerp, Belgium.
SORT1 Sequencing
Genomic DNA was extracted from peripheral blood according to standard procedures. For the resequencing of all 20 coding exons of SORT1 (RefSeq NM_002959.5), two multi-amplicon target panels were designed using the amplicon target amplification assay (Agilent, https://www.agilent.com). Primers for multiplex PCR were designed using the mPCR primer design software (Agilent, https://www.agilent.com); Goossens et al., 2009) . Specific target regions were amplified using multiplex PCR, Individual barcodes (Illumina Nextera XT) were incorporated, in a universal PCR step. Bridge amplification and sequencing of barcoded samples was performed using an Illumina MiSeq platform, with the Illumina V2 reagent kit, generating 250 bp paired-end reads.
internal sequencing primers and the BigDye Terminator Cycle sequencing kit v3.1 (Applied Biosystems, Foster City, CA) and analyzed on an automated ABI3730 DNA Analyzer (Applied Biosystems). Sequences were analyzed using both the software packages NovoSNP (Weckx et al., 2005) and Lasergene (DNASTAR, Madison WI USA).
gDNA numbering of SORT1 variants is relative to nucleotide 1 of the reference sequence NG_028280.1. Coding variants were numbered relative to the translation initiation codon in the largest SORT1 transcript (RefSeq NM_002959.5). Amino acid numbering is according to the largest SORT1 protein isoform (GenPept Accession Number NP_002950.3).
Haplotype sharing analysis
Allele sharing was investigated using eight polymorphic STR markers at chromosome 1p13.3
and surrounding SORT1 (D1S239, D1S2688, ATA42G12, D1S248, D1S2778, D1S2792, D1S221, D1S2651). STRs were PCR-amplified using fluorescently-labelled primers and sized using GeneScan 500 Liz Size Standard (Applied Biosystems) on an ABI3730xl DNA Analyzer (Applied Biosystems). Alleles were scored with Local Genotype Viewer.
In silico predictions
The CADD_Phred score (http://cadd.gs.washington.edu/score) was used to predict the impact of non-synonymous variants (Kircher et al., 2014 ).
Statistical analysis
Rare variants were defined as variants with a minor allele frequency (MAF) ≤1% and were included in a rare variant burden analysis for individuals originating from Belgium, Spain, Italy and Portugal. Rare variant burden analysis was performed by collapsing alleles of all rare variants across the full SORT1 coding sequence, separately for each functional protein domain, or for rare variants located in the predicted GRN binding site (aa 281-320), using an optimized sequence kernel association test (SKAT-O test), adjusted for sample size <2,000. SKAT-O meta-analysis was performed using Meta_SKAT and corrected for ethnicity. Presented SKAT-O p-values represent the p-values over ρ=1, which represents a burden analysis. Functional protein domains were determined according to Uniprot accession number Q99523.
Results
SORT1 variants in the Belgian cohorts
Sequencing of the SORT1 coding region in the Belgian patient/control cohorts identified five rare (MAF ≤1%), non-synonymous variants in eight index patients that were absent in the Belgian control cohort. (Table 1) . Together, the SORT1 carrier frequency was 1.3% (8/636 patients) in the Belgian FTD patient cohort. Four variants, p.Lys302Glu, p.Gly310Ala, p.Arg392Gln and flanking SORT1 indicated that all for carriers were sharing alleles in a genomic segment of 1 Mb.
In addition, we identified in SORT1, five rare variants that were present in both patients and control individuals ( (Fig. 1 ). In the Belgian control cohort, we identified two variants that were present only in control persons (Table S4) , of which p.Glu148Asp is located in the β-propeller domain and p.Arg716Gln at the 10 CC module (Fig. 1) . All rare variants identified in patients and control persons or in control persons-only, are present in the ExAc database (Table S2) .
A burden analysis, collapsing all rare SORT1 variants across the whole protein, showed a significant enrichment in patients (21/1,272 alleles = 1.6%) compared to control persons (20/2,132 alleles = 0.9%; p = 0.04) ( Table 3 & Table S5 ). The association appeared to be driven by the rare variants burden in the β-propeller domain in FTD patients (18/1,272 alleles = 1.4%) compared to controls (16/2,132 = 0.7%; p = 0.04) (Table S5) , and particularly by these variants that are located in the predicted binding region for GRN, 5/1,272 alleles = 0.4% in patients and 0/2,150 = 0% in controls (p = 0.001) (Table S5) .
SORT1 variants in the European cohorts
Aiming at replication our findings in the Belgian cohorts, we sequenced the entire coding sequence of SORT1 in three independently sampled patient/control cohorts in Spain, Italy and
Portugal by partners of the EU EOD Consortium (Table S1) (Table S4 ). All patient-only variants, identified in the overall European cohort, affect evolutionary highly conserved amino acid codons (Fig. S1 ), of which three received a pathogenicity CADD_Phred score above 20 (Table 1) . Two variants, p.Glu421Lys and p.Asp629Glu, were absent in the ExAc database, while the other five were observed with varying frequencies (Table 1) . Of four variants, observed in Belgian patients-only (p.Lys302Glu) or in patients and controls (p.Ile124Val, p.Asp358Tyr and p.Glu447Gly), three were present in European patients and control persons and one in controls-only (Fig. 1) (Table   S5 ).
Clinical characteristics of SORT1 patient-only variant carriers
The SORT1 carriers that were identified in the Belgian and the European patient cohorts (Table   1) , had a clinical diagnosis of FTD and a subtype diagnosis of bvFTD (n=12), PNFA (n=2), SD (n=1), or PPA not further specified (n=1) ( Table 1) . For one patient the clinical subtype diagnosis was not defined. The average age at onset of all patients was 64.6 ± 8.9 years (range 48-77).
Eight of the 17 SORT1 variant carriers had a known positive familial history of neurodegenerative disease. Previous genetic profiling of common FTD-ALS genes (MAPT, GRN, C9orf72, TBK1, SOD1, VCP, FUS and TARDBP) and AD genes (APP, PSEN1, PSEN2) in patients and control persons were negative.
For 6/8 Belgian and 7/9 European carriers, we were able to retrieve detailed clinical information from their medical record (Table 4) , which was compatible with a FTD phenotype. The bvFTD carriers had various behavioral problems ranging from apathy, loss of empathy, loss of interest, loss of hygiene, social withdrawal and decreased spontaneous speech to disinhibition, mental rigidity, hyperorality, perseveration and compulsive or stereotyped behavior. Also attention M A N U S C R I P T
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11 deficits and executive dysfunctions were present and, in a few patients, memory complaints and decreased orientation. Word retrieval deficits were the most frequent reported language problem.
Extrapyramidal rigidity and/or hypo-or bradykinesia were reported in three patients. Structural and functional neuroimaging findings were variable, but compatible with FTD. In three patients, leukoaraiosis was present, potentially contributing to the cognitive decline
Discussion
In this study, we investigated whether genetic variation in SORT1 might contribute to the genetic etiology of FTD by sequencing the complete coding region of SORT1 in independent patient/control cohorts. We identified multiple rare non-synonymous variants that were either present in patients-only, controls-only or in both patients and controls. A burden analysis collapsing all rare variants across the protein showed an excess of coding SORT1 variants in patients compared to controls in both the Belgian (p = 0.04) and Spanish (p = 0.02) cohorts. This SORT1 is composed of three protein domains, a β-propeller, a 10CC module and a transmembrane domain (Fig. 1) . The propeller region is composed of ten blades and forms a large tunnel in which the ligands, including GRN, can bind (Zheng et al., 2011) . The 10CC module comprises 10 cysteine residues that form five disulfide bonds. Based on the crystal structure of SORT1, it is believed that the 10CC module is important for the stabilization of the β-propeller by interacting with its outer surface (Quistgaard et al., 2009 ).
Of the 11 patient-only variants in SORT1, seven received a pathogenicity CADD_Phred score above 20, indicating that these rare variants are among the 1% most deleterious substitutions in the human genome (Kircher et al., 2014) . Further, seven patient-only variants are located in the β- the predicted binding site for GRN (Fig. 1) . Based on their localization, it can be hypothesized that these variants might abolish binding between GRN and SORT1. However, a functional follow-up study will be needed to confirm these hypotheses.
Previous reports have shown genome-wide association between common variants, located in the proximity of SORT1, and GRN plasma levels in control persons, FTD patients and patients carrying a GRN mutation (Carrasquillo et al., 2010) . In addition, using an unbiased ligand binding assay, SORT1 was identified as a neuronal receptor for GRN (Hu et al., 2010) . It was shown that, in a stressed central nervous system, GRN is secreted by activated microglia and undergoes rapid endocytosis upon binding to SORT1, which is expressed on the neuronal cell surface. These findings make SORT1 one of the most important neuronal receptors to regulate extracellular GRN levels (Hu et al., 2010) . However, it was shown that the neurotrophic effects of GRN are not dependent on the binding between GRN and SORT1, indicating that SORT1 may not be the only neuronal receptor for GRN (De Muynck et al., 2013; Gass et al., 2012) .
Here, we reported for the first time a genetic association of rare non-synonymous variants in 2) We sequenced the SORT1 gene and found rare variants that were significantly more frequent in FTD patients than control persons.
3) The patient-only variants were found in the major domains of SORT1 including the binding domain of SORT1 and GRN.
